Physician profile
Kevin Bender
NPI 1922010008
$13,701.54
in general payments reported to CMS, 2019-2025
45 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $1,550 · 2021: $1,686 · 2022: $2,014 · 2023: $2,662 · 2024: $2,338 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,579 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,579.12 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,854.58 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,284.96 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,036.98 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $955.66 | 2019-2025 | Repatha, Repatha, Evenity |
| Heartflow, INC. | $813.19 | 2022-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $802.49 | 2019-2025 | |
| Amarin Pharma, INC. | $702.15 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $664.97 | 2019-2023 | |
| Medtronic, INC. | $568.19 | 2021-2025 | Corevalve Evolut R, Micra |
| Astrazeneca Pharmaceuticals Lp | $556.31 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $489.55 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $486.37 | 2019-2024 | Livalo |
| Boston Scientific Corporation | $447.31 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $360.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $349.52 | 2021-2025 | Verquvo, Capvaxive |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $308.86 | 2019-2025 | Aveir |
| Pfizer INC. | $277.71 | 2020-2025 | |
| Esperion Therapeutics, INC. | $272.06 | 2020-2025 | Nexletol |
| Cvrx, INC. | $160.28 | 2022-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.96 | 2020-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $122.13 | 2019-2025 | Amvuttra, Givlaari, Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $121.12 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $117.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $95.41 | 2023-2024 | Opsumit |
| Arbor Pharmaceuticals, INC. | $93.31 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $85.97 | 2023-2024 | Inpefa |
| Idorsia Pharmaceuticals US INC | $68.19 | 2022-2023 | Quviviq |
| Medtronic Vascular, INC. | $67.45 | 2020 | |
| Philips North America LLC | $64.95 | 2024 | (5091) Amb Mon & Diag Und |
| Lundbeck LLC | $64.28 | 2019 | |
| Atricure, INC. | $50.77 | 2021-2024 | |
| Exact Sciences Corporation | $34.03 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $29.31 | 2023 | Mounjaro |
| Agepha Pharma Fz LLC | $29.28 | 2024 | Lodoco |
| Medicure Pharma INC. | $26.66 | 2021 | |
| Cleerly, INC. | $25.09 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astellas Pharma US INC | $22.22 | 2019 | |
| Infobionic, INC | $19.42 | 2020 | |
| Ge Healthcare | $15.80 | 2022 | |
| Preventice Services, LLC | $15.23 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.